SCHEMBL16640380

SCHEMBL16640380

Fc1ccccc1-c1cnccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 3/20 0.55
FEN1 P39748 3/20 0.55
PIM1 P11309 1/20 0.55
NPC1 O15118 4/20 0.50
IDO1 P14902 1/20 0.47
RAB9A P51151 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
ADRA1A P35348 2/20 0.43
ADRA1B P35368 2/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
TERT O14746 2/20 0.43
TGFBR1 P36897 1/20 0.42
ADRA1D P25100 1/20 0.42
CASP6 P55212 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31140243 1.00 ALOX5AP (0.55) ALOX5APFEN1PIM1NPC1IDO1
SCHEMBL16640381 0.85 ALOX5AP (0.47) ALOX5APFEN1PIM1NPC1RAB9A
SCHEMBL12853973 0.83 ALOX5AP (0.50) ALOX5APFEN1PIM1ADRA1AADRA1B
SCHEMBL12853984 0.83 ALOX5AP (0.50) ALOX5APFEN1PIM1ADRA1AADRA1B
SCHEMBL31444423 0.82 ALOX5AP (0.45) ALOX5APFEN1PIM1NPC1RAB9A
SCHEMBL4028337 0.77 ALOX5AP (0.54) ALOX5APFEN1PIM1NPC1RAB9A
SCHEMBL1780998 0.77 KDM4E (0.56) NPC1IDO1RAB9ATDP1L3MBTL1
SCHEMBL4073407 0.76 ADRA1A (0.43) ALOX5APFEN1PIM1ADRA1AADRA1B
SCHEMBL31681935 0.76 IDO1 (0.47) ALOX5APFEN1IDO1ADRA1AADRA1B
SCHEMBL2556892 0.76 DCTPP1 (0.54) ALOX5APFEN1NPC1IDO1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103987707-B The base heterocyclic radical benzamide compound of pyrazoles 4 and application method 霍夫曼-拉罗奇有限公司 2017-11-07 CN claimed
CN-110407816-A A kind of compound and application and device using the compound UNIV TSINGHUA 2019-11-05 CN disclosed
EP-3057963-B1 PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INT (DE) 2019-06-19 EP disclosed
US-9233953-B2 Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-12 US disclosed
US-9233953-B2 Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-12 US disclosed
WO-2015055698-A1 PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-23 WO disclosed
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-16 US disclosed
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-16 US disclosed
CN-102762582-A Metal complexes comprising diazabenzimidazole carbene ligands and their use in OLEDs BASF SE 2012-10-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament SLC6A7, SLC7A11, SLC7A1 ALOX5AP 1864/4885FEN1 3809/4885PIM1 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.